Real-World Study of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the US

References

• Davis J, Trudo F, Siddall J, Small M. Burden of asthma among patients adherent to ICS/LABA: a real-world study. J Asthma. 2019;56(3):332–340. doi:10.1080/02770903.2018.1455858
   PubMed Web of Science ®Google Scholar
• Lee LK, Obi E, Paknis B, Kavati A, Chipps B. Asthma control and disease burden in patients with asthma and allergic comorbidities. J Asthma. 2018;55(2):208–219. doi:10.1080/02770903.2017.1316394
   PubMed Web of Science ®Google Scholar
• Fernandes AGO, Souza-Machado C, Coelho RCP, et al. Risk factors for death in patients with severe asthma. J Bras Pneumol. 2014;40(4):364–372. doi:10.1590/S1806-37132014000400003
   PubMed Web of Science ®Google Scholar
• Katz PP, Yelin EH, Eisner MD, Blanc PD. Perceived control of asthma and quality of life among adults with asthma. Ann Allergy Asthma Immunol. 2002;89(3):251–258. doi:10.1016/S1081-1206(10)61951-5
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Ghushchyan VH, Campbell JD, Globe G, Bender B, Magid DJ. Measuring the cost of poor asthma control and exacerbations. J Asthma. 2017;54(1):24–31. doi:10.1080/02770903.2016.1194430
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Slejko JF, Ghushchyan VH, et al. The relationship between asthma, asthma control and economic outcomes in the United States. J Asthma. 2014;51(7):769–778. doi:10.3109/02770903.2014.906607
   PubMed Web of Science ®Google Scholar
• Tran TN, MacLachlan S, Hicks W, et al. Oral corticosteroid treatment patterns of patients in the United States with persistent asthma. J Allergy Clin Immunol Pract. 2021;9(1):338–346. e333. doi:10.1016/j.jaip.2020.06.019
   PubMed Web of Science ®Google Scholar
• Tavakoli H, Mark FitzGerald J, Lynd LD, Sadatsafavi M. Predictors of inappropriate and excessive use of reliever medications in asthma: a 16-year population-based study. BMC Pulm Med. 2018;18(1):1–8. doi:10.1186/s12890-018-0598-4
   PubMedGoogle Scholar
• FitzGerald JM, Tavakoli H, Lynd LD, Al Efraij K, Sadatsafavi M. The impact of inappropriate use of short acting beta agonists in asthma. Respir Med. 2017;131:135–140. doi:10.1016/j.rmed.2017.08.014
   PubMed Web of Science ®Google Scholar
• Heatley H, Tran TN, Bourdin A, et al. Observational UK cohort study to describe intermittent oral corticosteroid prescribing patterns and their association with adverse outcomes in asthma. Thorax. 2022;78(9):860–867. doi:10.1136/thorax-2022-219642
   PubMedGoogle Scholar
• Manson SC, Brown RE, Cerulli A, Vidaurre CF. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med. 2009;103(7):975–994. doi:10.1016/j.rmed.2009.01.003
   PubMed Web of Science ®Google Scholar
• Waljee AK, Rogers MA, Lin P, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017;357:j1415. doi:10.1136/bmj.j1415
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention; 2023. Available from: https://ginasthma.org/wp-content/uploads/2023/05/GINA-2023-Full-Report-2023-WMS.pdf. Accessed May, 2023.
   Google Scholar
• GSK. FDA approves Trelegy Ellipta as the first once-daily single inhaler triple therapy for the treatment of both asthma and COPD in the US. Press release September 9, 2020. Available from: https://www.gsk.com/en-gb/media/press-releases/fda-approves-trelegy-ellipta-as-The-first-once-daily-single-inhaler-triple-therapy-for-The-treatment-of-both-asthma-and-copd-in-The-us. Accessed February 3, 2023.
   Google Scholar
• FitzGerald JM, Sadatsafavi M. Triple therapy in a single inhaler: a new option for uncontrolled asthma. Lancet. 2019;394(10210):1690–1692. doi:10.1016/S0140-6736(19)32216-0
   PubMed Web of Science ®Google Scholar
• Pavord ID, Beasley R, Agusti A, et al. After asthma: redefining airways diseases. Lancet. 2018;391(10118):350–400. doi:10.1016/S0140-6736(17)30879-6
   PubMed Web of Science ®Google Scholar
• Schatz M, Meckley LM, Kim M, Stockwell BT, Castro M. Asthma exacerbation rates in adults are unchanged over a 5-year period despite high-intensity therapy. J Allergy Clin Immunol Pract. 2014;2(5):570–574.e571. doi:10.1016/j.jaip.2014.05.002
   PubMed Web of Science ®Google Scholar
• McDonald VM, Hiles SA, Godbout K, et al. Treatable traits can be identified in a severe asthma registry and predict future exacerbations. Respirology. 2019;24(1):37–47. doi:10.1111/resp.13389
   PubMed Web of Science ®Google Scholar
• Casey MF, Richardson LD, Weinstock M, Lin MP. Cost variation and revisit rate for adult patients with asthma presenting to the emergency department. Am J Emerg Med. 2022;61:179–183. doi:10.1016/j.ajem.2022.09.021
   PubMed Web of Science ®Google Scholar
• Suruki RY, Daugherty JB, Boudiaf N, Albers FC. The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA. BMC Pulm Med. 2017;17(1):74. doi:10.1186/s12890-017-0409-3
   PubMed Web of Science ®Google Scholar
• Lee LA, Bailes Z, Barnes N, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2021;9(1):69–84. doi:10.1016/S2213-2600(20)30389-1
   PubMed Web of Science ®Google Scholar
• Stanford RH, Shah MB, D’Souza AO, Dhamane AD, Schatz M. Short-acting β-agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol. 2012;109(6):403–407. doi:10.1016/j.anai.2012.08.014
   PubMed Web of Science ®Google Scholar
• Nwaru BI, Ekström M, Hasvold P, Wiklund F, Telg G, Janson C. Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J. 2020;55(4):1901872. doi:10.1183/13993003.01872-2019
   PubMed Web of Science ®Google Scholar
• Quint JK, Arnetorp S, Kocks JWH, et al. Short-acting beta-2-agonist exposure and severe asthma exacerbations: SABINA findings from Europe and North America. J Allergy Clin Immunol Pract. 2022;10(9):2297–2309.e2210. doi:10.1016/j.jaip.2022.02.047
   PubMed Web of Science ®Google Scholar
• Noorduyn SG, Qian C, Johnston KM, et al. SABA use as an indicator for asthma exacerbation risk: an observational cohort study (SABINA Canada). ERJ Open Res. 2022;8(3):00140–02022. doi:10.1183/23120541.00140-2022
   PubMedGoogle Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa1713901
   PubMed Web of Science ®Google Scholar
• Ismaila AS, Haeussler K, Czira A, et al. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) triple therapy compared with other therapies for the treatment of COPD: a network meta-analysis. Adv Ther. 2022;39(9):3957–3978. doi:10.1007/s12325-022-02231-0
   PubMed Web of Science ®Google Scholar
• Hanania NA, Bunner SH, Bengtson LGS, Ismaila AS, Bogart M. COPD exacerbations, costs, and health care resource utilization before and after initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in routine care in the USA. Int J Chron Obstruct Pulmon Dis. 2023;18:407–418. doi:10.2147/COPD.S378867
   PubMed Web of Science ®Google Scholar
• Uchida A, Sakaue K, Inoue H. Epidemiology of asthma-chronic obstructive pulmonary disease overlap (ACO). Allergol Int. 2018;67(2):165–171. doi:10.1016/j.alit.2018.02.002
   PubMed Web of Science ®Google Scholar